510(k) vs PMA: Differences in FDA Device Approval and Clearance

When a Food and Drug Administration (FDA) reviewer opens a premarket submission, the pathway your team selected determines the evidence standard, review timeline, user fee, and post-market obligations your company will carry for as long as the device stays on the market. Choose well, and the submission moves on the standard you planned around. Choose the wrong pathway, and you can add months of rework, misallocate clinical resources, and end up with a submission strategy that never matched the device’s risk profile in the first place.

For medical device teams preparing a first submission or launching a new product line, the 510(k) vs Premarket Approval (PMA) decision shapes every downstream activity. This guide walks through how the FDA classifies devices, where the two pathways diverge, how to determine which one applies to your device, and the documentation failures that most often delay a submission.

What Is the FDA Device Approval and Clearance Process?

FDA regulates medical devices through a risk-based classification system that assigns each device to one of three classes, and that classification determines which premarket pathway applies and how much evidence FDA requires before a device can reach the U.S. market.

Class I devices carry the lowest risk and are subject only to general controls. Most are exempt from premarket review entirely. Class II devices carry a moderate risk, require general and special controls, and typically undergo the 510(k) pathway. Class III devices support or sustain human life, present a potentially unreasonable risk of illness or injury, and require the most rigorous review through PMA. FDA’s device classification system is the starting point for any pathway decision.

510(k) Clearance Explained

The 510(k) premarket notification derives its authority from Section 510(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and is a comparative pathway. FDA evaluates whether the new device is substantially equivalent to a legally marketed predicate device.

FDA’s substantial equivalence review first compares the new device’s intended use with that of the predicate. If the intended use differs, the FDA finds the device Not Substantially Equivalent (NSE). If the intended use matches, the FDA then evaluates whether differences in technological characteristics raise new questions of safety or effectiveness. The new device may differ from the predicate in materials, design, or energy source if the submitter demonstrates the device is at least as safe and effective.

Clinical data is conditional for 510(k) submissions, not universally required. When technological differences raise new safety questions, FDA can and does request clinical evidence during substantive review. The FY 2026 standard user fee is $26,067, with a reduced fee of $6,517 for small businesses with gross receipts of $100 million or less.

PMA Approval Explained

PMA is the FDA process for evaluating the safety and effectiveness of Class III medical devices under Section 515 of the FD&C Act. Class III includes devices such as implantable pacemakers, breast implants, and implantable cardioverter defibrillators.

Before approving a PMA, the sponsor must provide valid scientific evidence demonstrating reasonable assurance of safety and effectiveness for the device’s intended use, without reference to any predicate. Clinical studies supporting a PMA must comply with Investigational Device Exemption (IDE) regulations, along with informed consent and Institutional Review Board (IRB) oversight requirements.

FDA’s PMA process uses an 180-day review clock. The FY 2026 standard user fee is $579,272, with a small business fee of $144,818. PMA development costs extend well beyond the application fee itself, especially when clinical studies and post-approval obligations are involved.

510(k) vs PMA: The Core Differences

The two pathways diverge across nearly every dimension that affects submission planning, resource allocation, and post-market compliance. The table below summarizes where, using the FY 2026 Medical Device User Fee Amendments (MDUFA) fee schedule, the figures.

PMA fees are substantial, which makes total lifecycle cost planning a material part of the business case. Both pathways carry identical obligations under Medical Device Reporting (MDR) rules, Quality System and Good Manufacturing Practice (GMP) requirements, and Section 522 postmarket surveillance studies.

How to Determine Which Pathway Your Device Requires

Start with the FDA Product Classification Database. Searching by device name identifies the closest generic device type and its three-letter product code, which helps you determine the likely submission pathway.

If the database indicates 510(k) is required, the next step is searching for a single legally marketed predicate with the same intended use, since split predicates, or relying on different devices for intended use and technological characteristics, are inconsistent with the 510(k) regulatory standard. A valid predicate must meet one of these conditions:

• Pre-amendment marketing: The device was legally marketed before May 28, 1976.
• Downward reclassification: FDA reclassified the device from Class III to Class II or I.
• Prior substantial equivalence: The device was found to be substantially equivalent through a prior 510(k) submission.
• De Novo authorization: The device was granted marketing authorization via the De Novo process.

When no suitable predicate exists, the device team must assess whether general controls alone, or general and special controls together, provide reasonable assurance of safety and effectiveness. If controls are sufficient and the device carries low-to-moderate risk, the De Novo classification pathway applies. If controls are insufficient and the device is high-risk or life-sustaining, PMA is the route.

For novel devices without predicates, De Novo can be a strategic choice. When the FDA grants a De Novo request, a new classification regulation is established for the entire device type, and the newly classified device becomes a valid predicate for future 510(k) submissions. The De Novo fee is materially lower than the standard PMA application fee.

For ambiguous situations, such as novel technology, unclear classification or regulatory pathway questions, or potential combination products, FDA recommends seeking early feedback through a Pre-Submission (Q-Sub) before committing to a pathway. For formal combination-product jurisdiction determinations, sponsors may instead need a Request for Designation.

Common Documentation Failures That Delay FDA Submissions

FDA uses the Refuse to Accept (RTA) checklist to screen submissions for basic completeness before substantive review. A 510(k) with documentation failures can substantially extend the review process because hold time from Additional Information (AI) requests does not count toward the review clock.

Three deficiency patterns recur most frequently across both pathways:

• Broken requirements traceability: Missing links between requirements and verification are a common inspection finding because ambiguous design inputs make it difficult to demonstrate that those inputs have been verified.
• Incomplete design history file: Under design control requirements, manufacturers must maintain a Design History File (DHF) demonstrating that the design was developed in accordance with design controls. FDA warning letters have cited broad DHF deficiencies, including missing design plans, input requirements, outputs, reviews, risk analyses, verification and validation, and design transfer documentation.
• Risk file traceability gaps: ISO 14971:2019 requires the risk management file to provide traceability for each identified hazard, and reviewers have flagged misapplication of benefit-risk analyses in ways that do not support the record’s regulatory purpose.

For PMA submissions specifically, FDA regulations state that applications lacking required information may not be approved, and FDA may refuse to file an application that is not sufficiently complete to permit substantive review. DHF integrity and traceability deficiencies identified during pre-approval facility inspections can independently block PMA approval, regardless of the adequacy of the written submission.

How Jama Connect® Supports 510(k) vs PMA FDA Device Approval

When teams manage design inputs, outputs, risk items, and test cases across disconnected systems, the traceability gaps described above surface late, delaying submissions. Jama Connect is a cloud-based requirements management and traceability platform for complex, regulated product development that connects those records in a single system across the full development lifecycle, so coverage gaps are identified early, while there is still time to close them, rather than during an RTA screen.

Its medical device framework aligns with ISO 13485, 21 CFR 820.30, IEC 62304, and ISO 14971, and Review Center supports 21 CFR Part 11-compliant electronic signatures for formal sign-off. Dexcom reported a 60% improvement in systems engineering efficiency with Jama Connect by centralizing requirements and applying Live Traceability™ throughout its development process.

Choose the Right FDA Pathway Early

The pathway decision is not only a regulatory formality at the front of a program. It sets the clinical evidence you have to generate, the people and budget you commit, and the reporting you owe the FDA for the life of the device, which is why a pathway chosen late or for the wrong reasons is expensive to unwind.

Jama Connect supports this work by keeping requirements, design outputs, risk records, and verification linked in one place, so the traceability an FDA reviewer expects is a byproduct of development rather than a reconstruction effort before submission. If your team is spending more time assembling documentation than building the device itself, start a free 30-day trial of Jama Connect.

Frequently Asked Questions About 510(k) vs PMA

Is a 510(k) faster than a PMA?

Yes, by a significant margin. A 510(k) is typically reviewed on a shorter timeline than an original PMA, and the real gap is often larger because PMA applicants must complete IDE-approved clinical trials before they can even submit. Third-party review through the Accredited Persons Program can shorten 510(k) review in some cases, and clean DHF and traceability practices reduce preparation time before submission.

Can a device switch from a PMA to a 510(k) pathway?

It can, but only through formal FDA reclassification. FDA must change the device type from Class III to Class II or Class I after determining that general controls alone, or general and special controls together, provide reasonable assurance of safety and effectiveness. Manufacturers can also petition the FDA for downward reclassification. FDA initiated a proceeding to reclassify automated external defibrillators (AEDs) from Class III to Class II amid concerns about recalls and device malfunctions over a multi-year period.

What happens if no predicate device exists?

The De Novo classification pathway under Section 513(f)(2) of the FD&C Act provides a route for novel devices that carry low-to-moderate risk but lack a predicate. De Novo applies to new device types that fall outside the 510(k) framework because there is no legally marketed predicate, yet do not require a PMA because general and special controls can establish reasonable assurance of safety and effectiveness. FDA reviews these requests on a separate track, and the De Novo fee is materially lower than the PMA application fee.

Does FDA clearance mean the same thing as FDA approval?

No, and the distinction carries legal consequences. A 510(k) results in “clearance,” meaning the FDA found the device substantially equivalent to a predicate, while a PMA results in “approval,” meaning the FDA independently determined the device is safe and effective based on valid scientific evidence. Describing a 510(k)-cleared device as “FDA-approved” in marketing materials creates a misbranding risk under the FD&C Act and exposes the company to advertising and consumer protection disputes.

This article was authored by Tom Rish and published on June 18, 2026.